Tel: +1 919 929 3807

Fax: +1 919 929 3935
meetings@isth.org

International Society on Thrombosis and Haemostasis (ISTH) 
610 Jones Ferry Road, Suite 205 Carrboro, NC 27510 USA
© COPYRIGHT 2019. ALL RIGHTS RESERVED

  • Facebook - Black Circle
  • Twitter - Black Circle
  • LinkedIn - Black Circle
  • Instagram - Black Circle
  • YouTube - Black Circle

ABSTRACTS

Abstract Submission Opens December 3

ISTH 2020 Congress abstract submission will open on December 3, 2019. Be prepared and review the important dates and guidelines below:
 

  • December 3, 2019:
    Abstract Submission Opens

  • February 4, 2020 at 17:00 EST (U.S.):
    Abstract Submission Closes

  • March 13, 2020:
    Abstract Titles Released

  • May 20, 2020:
    Late-Breaking Abstract Submission Opens

  • June 3, 2020 at 17:00 EST (U.S.):
    Late-Breaking Abstract Submission Closes
     

ABSTRACT GUIDELINES

Sections on This Page

Main Topics

  • Arterial Thromboembolism 

  • Coagulation & Natural Anticoagulants 

  • Diagnostics and OMICs 

  • Fibrinolysis and Proteolysis 

  • Hemophilia and Rare Bleeding Disorders 

  • Pediatrics

  • Platelet Disorders and von Willebrand Disease

  • Platelets and Megakaryocytes 

  • Role of Hemostatic Systems in Cancer, Inflammation and Immunity

  • Thrombotic Microangiopathies

  • Vascular Biology

  • Venous Thromboembolism 

  • Women’s Health

The content of the abstract must be related to one of the topics below. To ensure smooth scoring of papers, the topic of your work must be selected during the submission process.

Arterial Thromboembolism
Atherosclerosis
Acute Coronary Syndromes
Cerebrovascular Disorders
Peripheral Artery Disease
Cardiovascular Risk Factors

Coagulation & Natural Anticoagulants
Animal Models in Thrombosis & Hemostasis
Coagulation Factors & Inhibitors
Contact Pathway
Critical Care and Perioperative
FVIII/IX
Hemostasis & Organ Dysfunction
Microparticles
Protein C Pathway
Regulation of Coagulation
Tissue Factor Pathway

Diagnostics and OMICs
Biomarkers of Thrombosis & Hemostasis
Blood Components & Management
Cellular Therapies
Epigenetics, OMICs & Bioinformatics
Laboratory Diagnostics
Nanotechnology & Novel Biomolecules

Fibrinolysis and Proteolysis
Fibrinogen & Factor XIII
Fibrinolytic Factors & Inhibitors
Plasminogen Activation in the CNS and Immunity
Thrombolytic Therapy

Hemophilia and Rare Bleeding Disorders
Acquired Hemorrhagic Coagulation Disorders
Disseminated Intravascular Coagulation
Hemophilia - Basic
Hemophilia - Clinical
Hemophilia Gene Therapy
Management of Bleeding & Trauma
Novel Biotherapeutics in Hemophilia
Rare Bleeding Disorders

Nurses
Nurses & Allied Health

Pediatrics
Bleeding in Neonates & Children
Thrombosis in Neonates & Children

Platelet Disorders and von Willebrand Disease 
von Willebrand Factor Biology
VWF & von Willebrand Factor Disorders - Clinical Conditions
Platelet Antagonists & Novel Therapeutics
Antiplatelet Therapy
HIT
Acquired Thrombocytopenias
Inherited Thrombocytopenias
Platelet Function Disorders, Hereditary
Platelet Function Disorders, Acquired

Platelets and Megakaryocytes
Platelet Function & Interactions
Platelet Proteomics & Genomics
Platelet Receptors
Platelet Signaling
Megakaryocytes & Thrombopoiesis

Role of Hemostatic System in Cancer, Inflammation and Immunity 
Platelets & Inflammation
Platelets and Cancer
Platelets and Infection
Coagulation Proteins Beyond Hemostasis
Proteases & Cancer
Complement & Hemostatic System
Infection & Hemostatic Factors

Thrombotic Microangiopathies
ADAMTS13 & TTP
Antiphospholipid Syndrome
HUS 
Non HUS/TTP Microangiopathies

Vascular Biology
Blood Cells & Vessel Wall
Endothelial Cell Signaling
Inflammation & Sepsis
Innate & Adaptive Immunity
Non-coding RNAs
Protease Activated Receptors
Stem Cells & Vascular Cell Growth

Venous Thromboembolism and Cardioembolism
VTE Treatment
Genetic Risk Factors of Thrombosis
VTE Prophylaxis
VTE Diagnosis
Post-thrombotic Syndrome
Thrombophilia
VTE Epidemiology
Cancer Associated Thrombosis
Visceral Vein Thrombosis
Atrial Fibrillation
Artificial Valves

Women Health
Pregnancy & Pregnancy Complications
Estrogens and Progestinics

How to Submit an Abstract

  • Delegates who would like to present their work at the congress, either orally or as a poster, are invited to submit an abstract for consideration by the Scientific Committee.

  • ISTH Members and Non-Members are invited to submit abstracts.

  • There are no fees to submit an abstract.

  • Abstracts can only be submitted online via the abstract submission website that can be found in the section “Abstract Guidelines” on the official ISTH 2020 Congress website. Abstracts sent by post or email will not be accepted. No exceptions will be made.

  • The submitter will be required to create a user account in order to submit an abstract. This can be done through the registration system. Once logged in you will be able to select ‘Submit an Abstract’ from the tabs at the top.

  • Abstracts can be saved in "Draft” status and be re-edited and modified until the submission deadline (February 4, 2020, 17:00 Eastern Standard Time (U.S.)).

  • You can still make edits to abstracts that have been submitted, but you will need to re-submit it before the deadline to be considered.

  • The submitted/draft abstracts cannot be edited after the submission deadline.

  • Only abstracts that have been submitted properly will be considered for the congress.

  • Any technical questions regarding the submission website should be sent to isth2020@abstractserver.com. All other abstract related questions can be sent to abstracts@isth.org. 

 

General Guidelines

  • The abstract must address scientific questions, detail clinical observations, or contain primary scientific data.

  • Abstracts should be submitted in clear English to allow the reviewers to focus on the scientific content of the abstract. Non-English speaking authors are encouraged to have their abstract checked for grammar and spelling.

  • Please ensure your abstract does not contain spelling, grammar, or scientific mistakes, as it will be reproduced exactly as submitted. Linguistic accuracy is your responsibility. No proof reading will be done.

  • Do not slice results from the same study into multiple abstracts. The Scientific Committee reserves the right to reject abstracts when inappropriate slicing of data is suspected. Similarly, do not submit a copy or close copy of an abstract under more than 1 topic. Abstracts that appear to be submitted multiple times under different topics will be rejected.

  • All research and studies in submitted abstracts that involve human subjects or experimental animals must comply with the Declaration of Helsinki.

  • No revisions can be made after the abstract deadline.

ISTH Embargo Policy
IMPORTANT: Please review the ISTH Embargo Policy here.

 

Preparing an Abstract for Submission


Authors and Co-Authors

  • The first/presenting author is responsible for ensuring that all authors have read the abstract and agreed to be co-authors.

  • The presenting author of the abstract must be registered for the meeting. 

  • The submission of an abstract constitutes a formal commitment by the submitting (presenting) author to present the abstract (if accepted) in the session and the time assigned by the Scientific Committee. Registration fees will not be waived.

  • A maximum of 20 authors is permitted on each abstract, plus one (1) group.

  • Adding Co-authors: please fill out the family names, first names, and institution, city, country and email addresses of each co-authors.

 
Conflict of Interest
It is the intent of the ISTH to provide high-quality sessions focused on educational content that is free from commercial influence or bias. Thus the submitting/presenting author of an abstract is requested to declare any potential conflicts of interest for the presenting author during abstract submission.
 
Abstract Body

  • For standardization, the acceptable length of the abstract is a maximum of 300 words. This does not include the author’s details, titles, tables and figures.

  • Title: Clearly indicate the nature of the investigation. The abstract title and text may not contain trade names. The Scientific Committee reserves the right to replace trade names in accepted abstracts.

  • Background

  • Aims

  • Methods: Which should contain sufficient information to be able to understand the experimental design, the analytical techniques and the statistics used in the study

  • Results: Which should contain objective data to answer the scientific question(s). A maximum of two total tables or figures may be submitted with this section. Please be sure to number each table and figure and cite each table and figure in the abstract text.

  • Conclusion (or Conclusions): Which should provide only conclusions of the study directly supported by the results, along with implications for clinical practice, avoiding speculation and overgeneralization.

  • Other Items for Consideration

- In clinical studies, please state whether informed consent was obtained and whether the study was approved by a recognized medical ethics committee.
- If the research included in your abstract was supported by a pharmaceutical or diagnostics company, you can indicate this when submitting your abstract.
- Please indicate the funding agency of your work if applicable.
- Abbreviations should be defined.
- If off-label use of drugs was involved in the study, please state this clearly.

 
 
 
 
 

Table and Figures

  • Figures may be submitted with a maximum file size is 10 MB with a resolution of 300 dpi. Figures are allowed in the following formats: PNG, GIF, JPG.

  • Tables are allowed with a maximum size of 10 columns x 10 rows. Characters in your table will NOT count towards your 300 word count.

  • Tables should be added using the tool in the submitter and not as an image file. Once your table has been created, please remember to drag and drop it into your abstract body.

  • Your abstract may contain two (2) graphics, this can be a combination of the following: two (2) figures, two (2) tables, or one (1) figure and one (1) table.

Prior Publication
Authors will be permitted to submit their abstract to ISTH 2020 Congress and another journal/meeting as long as the data in the abstract has not been published/presented at the time of submission or will not be published prior to ISTH releasing the abstract (two weeks prior to the meeting). 

 

Abstracts submitted to regional or national hematology meetings can be submitted to the ISTH 2020 Congress for inclusion in the program.

 

If you have questions regarding prior publication please contact us at abstracts@isth.org

 

Language Setting of Your Keyboard
The keyboard configuration of computers in non-Western countries may cause problems with the printing of the abstracts when special non-Western characters are used. To avoid these problems the language setting of your computer should be changed.
 
To do this select "Start" then Settings", then "Control Panel" and then choosing "Keyboard." Once in this menu, set the language of your computer to English (United States) or US (International). Next, open MS Word (or the word processing software you are using) and set the font type to Arial.  
 
In the preparation of your abstract, if you require certain special characters that are not available, (e.g. '±', '®', 'μ'), use the insert symbol feature (special characters). To do this, select Arial as the font (unicoded, if possible), then select the required character, and copy and paste the symbol into the text of the abstract. If a special character is still not available, describe the character, e.g. 'alpha’.

 

After Submission
An international panel of experts will review the abstracts. Each abstract will be reviewed by 4-6 different experts. Abstracts may be selected for oral presentation, poster presentation, publication only or rejection. The first author will be notified in early-April 2020, at the email address provided during submission, about whether or not their abstract has been accepted.

The reviewers will judge the abstracts according to the following criteria:

  • Is the abstract original?

  • Does it address an important scientific question?

  • Is the abstract clearly written with all salient facts?

  • Does the work adhere to ethical guidelines?

  • Is there evidence of statistical method if appropriate?

  • Are the conclusions justified by the results?

 

Please note:

  • No revisions can be made after the abstract deadline.

  • The review and selection process for Late Breaking Abstracts will be highly competitive. No more than five (5) abstracts will be selected to be featured in one (1) Oral Communication Session. If your abstract is not chosen to be included in the Late Breaking Oral Communication Session, it will be rejected. Late Breaking Abstract Submission will open on May 20, 2020.

  • The best scoring abstracts will be selected for oral presentation.

  • Oral Presentation: Authors of abstracts selected for oral presentation will be informed about the date and time of the session. Presentation guidelines will be made available online.

  • Poster Presentation: Poster presenters will be informed about the date and time of the poster exhibition. Poster guidelines will be made available online. Posters will be organized within the session using the topics chosen by the submitter in the online system.

  • All accepted abstracts will be published online only as an addendum supplement to the ISTH open access journal, Research and Practice in Thrombosis and Haemostasis (RPTH) and will be made available on the ISTH 2020 Congress website on Monday, June 29, 2020 at 09:00 Eastern Standard Time.

Withdrawal Policy

If authors wish to withdraw their abstracts from presentation or publication they are requested to notify ISTH via e-mail to abstracts@isth.org before April 22, 2020. Withdrawn abstracts will not be presented nor will these be published. Due to Italian regulations if you wish to withdraw your abstract, we must be notified by April 22, 2020. 

Technical Requirements
The online abstract submission system works best with Internet Explorer 7.0 or higher or Mozilla Firefox 3.0 or higher. Cookies and JavaScript need to be enabled.